Investors Supporting Research to Advance the Treatment of Endocrine Diseases

Spruce is a privately held company that has completed its Series A financing round, raising a total of $28M to advance the clinical development of our lead drug candidate, Tildacerfont (SPR001). Our investors are:

Novo: Bringing promising ideas to life.

Novo is one of the key players in the international life science investment industry, and is currently investing in 76 portfolio companies. Our portfolio spans the entire range of life science development. From budding ideas that need financial and commercial nurturing, to well-established biomedical and bioindustrial companies that call for significant capital and a long term investor to accelerate growth.

Visit Website +

Rivervest: Investing in life science innovation.

RiverVest Venture Partners® focuses exclusively on innovations in life sciences, a field in which our team has significant research, clinical, operational and investment expertise. Our team’s deep domain experience allows us to identify, found and actively incubate promising life science companies, particularly in the medical device and biopharmaceutical industries. We provide practical advice and strategic leadership to help entrepreneurs drive early-stage companies forward.

Visit Website +

Congenital Adrenal Hyperplasia Clinical Trials 2019

Spruce also has ongoing collaborations with the National Institutes of Health (NIH) for longer duration study of the safety and efficacy of tildacerfont in adults 18+.
Learn More
 
If you are age 12+ and diagnosed with Congenital Adrenal Hyperplasia, we invite you to join our Natural History Study and Registry.

The CAH Natural History Study's mission is to learn more about CAH so researchers can work to improve the quality of life and the health of individuals with CAH, and to provide hope through the promise of new treatments.

Learn More

Spruce Biosciences is a clinical-stage biotechnology company developing novel therapies to better serve patients with rare endocrine disorders. Our team has extensive experience with managing patients with rare endocrine diseases as well as developing novel therapeutics to treat patients with unmet needs. As a team, we are committed to transforming the quality of life for patients who have been underserved by scientific innovation.